Merck and Pfizer Going To Court Over Korea FTC Fines; Lilly And GSK Watch From The Sidelines
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Merck, Sharp & Dohme Korea, Korea Otsuka Pharmaceuticals and Pfizer Korea are appealing the South Korea Fair Trade Commission decision to impose fines on the companies in January for unfair rebate provisions and other improper benefits to doctors and hospitalsYou may also be interested in...
Korean Ministry Plan To Order Penalty-based Price Cuts On Pharmaceuticals Faces Resistance From Global And Local Players
SEOUL - Imminent plans in the works by South Korea's Ministry for Health, Welfare and Family Affairs to cut retail drug prices by up to 20 percent are triggering opposition from both international pharmaceutical firms and local producers of generic products
Korean Ministry Plan To Order Penalty-based Price Cuts On Pharmaceuticals Faces Resistance From Global And Local Players
SEOUL - Imminent plans in the works by South Korea's Ministry for Health, Welfare and Family Affairs to cut retail drug prices by up to 20 percent are triggering opposition from both international pharmaceutical firms and local producers of generic products
Korean Government Fines Five Pharma Multinationals For Unfair Trade
SEOUL - South Korea's trade watchdog, the Fair Trade Commission, has imposed fines collectively totaling KRW 20.48 billion ($14.8 million) on seven pharmaceutical companies - including five multinationals - on charges of unfair provision of rebates and other improper benefits to doctors and hospitals
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports